Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 800 of 5804
-
New hope for bladder cancer patients who Can't take chemo?
Disease control OngoingA Phase II, Randomized, Multi-Center, Double-Blind, Comparative Global Study to Determine the Efficacy and Safety of Durvalumab in Combination With Olaparib for First-Line Treatment in Platinum-Ineligible Patients With Unresectable Stage IV Urothelial Cancer
Phase: PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
Immunotherapy may replace chemo in head and neck cancer trial
Disease control OngoingThe purpose of this study is to compare any good or bad effects of using pembrolizumab (an experimental drug) and radiation therapy (RT), compared to using cisplatin chemotherapy and radiation therapy (RT) in the treatment of patients with head and neck squamous cell carcinoma (H…
Phase: PHASE2 • Sponsor: Loren Mell, MD • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
Massive trial tests cheap drug to stop Post-C-Section hemorrhage
Prevention CompletedA randomized placebo-controlled trial of 11,000 women to assess whether tranexamic acid as prophylaxis lowers the risk of postpartum hemorrhage in women undergoing a cesarean delivery.
Phase: PHASE3 • Sponsor: The George Washington University Biostatistics Center • Aim: Prevention
Last updated Jun 27, 2026 14:02 UTC
-
New hope for young migraine sufferers: drug shows promise in landmark trial
Disease control OngoingThe main purpose of this study is to evaulate the efficacy and safety of galcanezumab in participants 6 to 17 years of age for the preventive treatment of episodic migraine. The primary objective is to demonstrate the superiority of galcanezumab versus placebo in the reduction of…
Phase: PHASE3 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 08:15 UTC
-
New immune combo shows promise against stubborn lymphoma
Disease control CompletedThis is a Phase 2 non-randomized, open label, uncontrolled, efficacy and safety study. Study participants will receive two priming doses of 0.5mL of DPX-Survivac 21 days apart and up to six 0.1ml maintenance injections every two months with low dose metronomic oral cyclophosphami…
Phase: PHASE2 • Sponsor: Sunnybrook Health Sciences Centre • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Shorter radiation after mastectomy may cut side effects
Disease control OngoingThis randomized phase III trial studies how well hypofractionated radiation therapy works in preventing recurrence in patients with stage IIa-IIIa cancer who have undergone mastectomy. Hypofractionated radiation therapy delivers higher doses of radiation therapy over a shorter pe…
Phase: PHASE3 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
New catheter method aims chemo directly at pancreatic tumors
Disease control Recruiting nowThe study is a multi-center, open-label, randomized active controlled study of subjects with locally advanced pancreatic adenocarcinoma which is unresectable.
Phase: PHASE3 • Sponsor: RenovoRx • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
Gene therapy shows promise for rare eye disease that causes blindness
Disease control CompletedThe goal of this clinical trial is to assess the efficacy and safety of GS010 gene therapy - (lenadogene nolparvovec) in subjects with LHON due to the G11778A ND4 mitochondrial mutation with a vision loss up to one year.
Phase: PHASE3 • Sponsor: GenSight Biologics • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
New drug combo shows promise for tough liver cancer
Disease control CompletedThe purpose of this study is to observe and preliminary explore the efficacy and safety of combination of Apatinib and SHR-1210 regimen in treating advanced hepatocellular carcinoma.
Phase: PHASE2 • Sponsor: Jiangsu HengRui Medicine Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
New drug combo may boost stem cell success in sickle cell disease
Disease control CompletedIn this study the investigators will prospectively investigate whether the addition of a 3-months long preconditioning with azathioprine to the alemtuzumab/TBI non-myeloablative conditioning results in improved disease-free survival and donor chimerism after allo-SCT in SCD patie…
Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
New hope for aggressive breast cancer: drug cocktails show promise in trial
Disease control OngoingThis study is to assess the efficacy and safety of olaparib monotherapy versus olaparib in combination with an inhibitor of ATR (Ataxia-Telangiectasia Mutated (ATM) and Rad3-related protein kinase (Ceralasertib \[AZD6738\]) and olaparib monotherapy versus olaparib in combination …
Phase: PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Rituximab vs. azathioprine: which drug better prevents EGPA flares?
Disease control CompletedThe purpose of this study is to investigate, after achievement of remission, the efficacy of rituximab compared with azathioprine maintenance therapy on duration of remission, in patients with relapsing or newly-diagnosed Eosinophilic granulomatosis with polyangiitis EPGA receivi…
Phase: PHASE3 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
New cocktail of drugs shows promise for Hard-to-Treat prostate cancer
Disease control OngoingThe purpose of this study is to: a) establish the recommended phase 2 dose (RP2D) and to evaluate the antitumor activity and safety of niraparib combination therapies (Combinations 1 and 2) and b) to determine the relative bioavailability of niraparib and abiraterone acetate (AA)…
Phase: PHASE2 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
New clip device could spare High-Risk heart patients from open surgery
Disease control OngoingThe objective of the study is to demonstrate the non-inferiority for clinical efficacy of an endovascular treatment strategy with the MitraClip® in comparison with a surgical treatment strategy in patients with severe primary mitral regurgitation judged eligible for anatomical re…
Phase: NA • Sponsor: Nantes University Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
Parent stem cells offer new hope for kids with blood cancer
Disease control OngoingThis is a Phase I/II study designed to evaluate the kinetics of hematopoietic reconstitution and the incidence of acute chronic GVHD after partially matched related donor hematopoietic cell transplantation using an αβTCR/CD19+ cell depleted graft.
Phase: PHASE1, PHASE2 • Sponsor: Nationwide Children's Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
New combo treatment matches standard for esophageal cancer
Disease control CompletedThis retrospective real-world study aimed to compare neoadjuvant immunochemotherapy (NICT) and neoadjuvant chemoradiotherapy (NCRT) followed by esophagectomy in patients with locally advanced esophageal squamous cell carcinoma (ESCC). A total of 203 consecutive patients treated a…
Phase: NA • Sponsor: Yongtao Han • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
Can primary care clinics help curb the opioid crisis? a major trial tests a Team-Based model
Disease control CompletedEffective treatment for opioid use disorders (OUDs) requires medications. Two medications for treating OUDs-buprenorphine and injectable naltrexone-can be prescribed in primary care (PC). However, despite the current opioid epidemic and expert recommendations that OUDs should be …
Phase: NA • Sponsor: Kaiser Permanente • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Heart pouch procedure may beat blood thinners for stroke prevention
Disease control CompletedThe study goal is to determine the clinical benefit of percutaneous catheter-based left atrial appendage (LAA) closure in patients with non-valvular atrial fibrillation (NVAF) at high risk of stroke (CHA2DS2-VASc Score ≥2) as well as high risk of bleeding as compared to best medi…
Phase: PHASE4 • Sponsor: Charite University, Berlin, Germany • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
Magic mushroom compound shows promise for tough depression
Symptom relief OngoingThe primary goal of this pilot study is to investigate whether psilocybin alters neuroplasticity in people with major depressive disorder. The primary hypothesis is that psilocybin will result in neuroplastic changes that parallel improvement in symptoms of depression.
Phase: PHASE1 • Sponsor: Yale University • Aim: Symptom relief
Last updated Jun 27, 2026 07:56 UTC
-
Sound waves vs. Parkinson's: new ultrasound treatment shows promise
Disease control CompletedThe objective of this study is to test the efficacy and safety of unilateral subthalamotomy performed using the ExAblate System for the treatment of Parkinson's disease (PD) motor features.
Phase: NA • Sponsor: InSightec • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC